Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
11 May 2022 On Corporate Governance The Company informs about the appointment of a new member in its Board of Directors       Download
05 Apr 2022 Liquidity and counterparty agreements The Company communicates that it has entered into a liquidity agreement with Bestinver S.V., S.A.  Download
29 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted on 28 March 2022 and end of the share buyback program Download
28 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 21 March 2022 and 25 March 2022 Download
21 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 March 2022 and 18 March 2022 Download

Pages

Date Title Description PDF
07 Nov 2019 Information on P&L ROVI releases the first nine months 2019 results presentation Download
03 Oct 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the third quarter of 2019 Download
05 Sep 2019 Others on business performance and financial information The Company informs about the construction of a second heparin plant in Granada Download
30 Jul 2019 Information on P&L ROVI releases the first half 2019 results presentation Download
30 Jul 2019 Information on P&L ROVI releases the press release related to the first half 2019 financial results Download

Pages